Core Insights - The article emphasizes the importance of value investing as a preferred strategy for identifying strong stocks in various market conditions [2] - Kiora Pharmaceuticals (KPRX) is highlighted as a stock to watch, currently holding a Zacks Rank of 2 (Buy) and a Value grade of A [3] Valuation Metrics - KPRX has a Price-to-Book (P/B) ratio of 0.45, significantly lower than the industry average of 1.27, indicating potential undervaluation [4] - The stock's P/CF (Price-to-Cash Flow) ratio stands at 7.31, compared to the industry's average of 10.25, further suggesting that KPRX may be undervalued [5] Earnings Outlook - The combination of KPRX's strong valuation metrics and positive earnings outlook positions it as an impressive value stock in the current market [6]

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm Eastern Time, Kiora's Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar. The presentation will be available live from this registration ...

Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 "In the first quarter, we executed a strategic partnership with TOI, which included a $16 million upfront payment, and raised $15 million from an equity offeri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or o ...

WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2024 KIORA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or other jurisdiction of incorporation) 001-36672 98-0443284 (Commission File Number) (IRS Employer Identification No.) 332 Encinitas Blvd. Suite 102 Encinitas, CA 92024 (858) 224-960 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 98-0443284 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of Incorporation or organization) FORM 10-Q x QUARTERLY REPORT PURSUANT TO SEC ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or ot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact Name of Registrant as Specified in Its Charter) Delaware 98-0443284 WASHINGTON, D.C. 20549 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...